Ironwood Pharmaceuticals | IRWD - Operating Expenses


Ironwood Pharmaceuticals reported $57.33M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Almirall EUR 517.4M 32K Dec/2025
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
Ardelyx USD 127.27M 7.15M Mar/2026
Astellas Pharma JPY 489.36B 52.69B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Charles River Laboratories USD 875.93M 42.48M Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Moderna USD 1.78B 242M Mar/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Pacira USD 172.75M 20.93M Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.11T 85.29B Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025